Baloxavir for COVID-19: real-time analysis

Download Image

Post

c19early.org

Baloxavir for COVID-19

1 study with 20 patients

Serious outcome risk

Baloxavir

Control

No significant improvements are seen in meta-analysis to date.

COVID-19 Baloxavir studies · October 2026

Outcome (studies)

Improvement

Relative risk · 95% CI

All studies (1)−200%

Viral clearance (1)−600%

RCTs (1)−200%

Late (1)−200%

00.511.5+

← Baloxavir
reduces riskIncreased
risk →

.hmva--anim-stagger .hmva__row{opacity:1}.hmva--anim .hmva__shade{opacity:var(--shade-opacity)}.hmva--anim-stagger .est .ci{transform:translateY(-50%)}.hmva--anim-stagger .est .pt{transform:translate(-50%,-50%)}.hmva--anim-stagger .hmva__bar{transform:none}.hmva--anim-settle .est .pt{left:calc(min(var(--pt), 1.5) / var(--max) * 100%)}.hmva--anim-settle .est .ci{left:calc(var(--lo) / var(--max) * 100%);width:calc((var(--hi) - var(--lo)) / var(--max) * 100%)}.hmva--anim-settle .hmva__bar--drug{width:calc(min(1, var(--rr)) * 100%)}.hmva--anim-settle .hmva__bar--control{width:calc(min(1, 1 / var(--rr)) * 100%)}


Oct 25 2020	Lou et al., European Journal of Pharmaceutical Sciences, doi:10.1016/j.ejps.2020.105631	Clinical Outcomes and Plasma Concentrations of Baloxavir Marboxil and Favipiravir in COVID-19 Patients: An Exploratory Randomized, Controlled Trial
Oct 25 2020	20% improved recovery (p=1) and 600% worse viral clearance (p=0.21). Small late stage RCT with 10 favipiravir, 10 baloxavir marboxil, and 10 control patients in China, showing no significant differences. The single-dose influenza regimen produced plasma levels far below the SARS-CoV-2 EC₅₀.